Clinical Trial of SYS6010SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors
Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-15
Target enrollment:
Participant gender:
Summary
The study consists of two phases. Phase 1b and Phase 2. Phase 1b aims to evaluate the safety, tolerability, and preliminary efficacy of SYS6010 as a monotherapy and in combination with SYH2051, and to determine the recommended Phase 2 dose (RP2D) for subsequent Phase 2 studies. Phase 2 aims to assess the efficacy and safety of SYS6010 monotherapy or in combination with SYH2051 compared to investigator-selected chemotherapy in patients with EGFR-expressing, unresectable locally advanced or metastatic advanced breast cancer.